Creative Biolabs Launches Integrated Veterinary Therapeutic Antibody Research Services

Creative Biolabs launched integrated research strategies for veterinary therapeutic antibody development on October 26, 2026, connecting proteomic target discovery, veterinary antigen generation and antibody characterization for early-stage companion-animal biologics research. The FinancialContent Business Page published the announcement.

What the Veterinary Antibody Services Cover

The services address three interconnected stages of early research. Creative Biolabs provides proteomic solutions for pet antibody target discovery, including mass spectrometry-based approaches, cell-surface proteomics and secretome analysis, to help researchers identify and compare proteins across biological samples.

For antigen generation, the company supports antigens designed for specific experimental applications, with recombinant proteins and synthetic peptides as options depending on target structure and intended use. The company states that differences in protein folding, epitope accessibility and post-translational modifications can influence whether an experimental antigen represents its native counterpart.

Antibody characterization services assess binding kinetics through surface plasmon resonance or biolayer interferometry, specificity, cross-reactivity, molecular stability and functional activity. Candy Swift is named as the company's contact for the announcement.

"As interest in precision veterinary medicine continues to grow, specialized research capabilities may help scientists investigate new therapeutic opportunities while addressing the biological complexity of animal disease," the company said.

Creative Biolabs' Research Scale

According to akta.pro company records, Creative Biolabs is a private contract research organization based in Shirley, NY that provides custom antibody discovery, engineering, characterization and biomanufacturing services to pharmaceutical, biotech and academic clients globally. The company was founded in 2014 and has a headcount range of 51-100. Its revenue estimate is $25 million-$50 million and its valuation estimate is $100 million-$250 million. The company offers approximately 100 different service points covering antibody and biotherapeutic development, and 294 articles or patents have cited its services or products.

Earlier Creative Biolabs Announcements

Creative Biolabs outlined a three-part evaluation approach for immunoliposomes on October 23, 2026, combining development, physicochemical characterization and in vitro release kinetics analysis, according to Business & Financial. On October 21, 2026, the company highlighted custom antibody production, ELISA kit development and chemiluminescent immunoassay services for biomarker research, according to the FinancialContent Business Page. On October 19, 2026, it highlighted three AI platforms for bispecific antibody design, ADC development and antibody developability optimization, according to Business & Financial.

The services are intended to support research and development, and their availability does not establish the clinical efficacy or regulatory approval of any investigational veterinary therapy.